Shingles Vaccine Halves Serious Cardiac Events in Heart Disease Patients, Landmark Study at ACC.26 Highlights Broader Cardioprotective Benefits.

People living with pre-existing atherosclerotic heart disease who received a shingles vaccine experienced a remarkably lower rate of serious heart-related events within a year compared with their unvaccinated counterparts, a reduction approaching nearly fifty percent. This significant finding, which underscores a crucial link between vaccination and cardiovascular health, is among the pivotal research being presented at the American College of Cardiology’s Annual Scientific Session (ACC.26), a leading global forum for advancing cardiovascular science and patient care. The study offers compelling new evidence for the multifaceted benefits of the herpes zoster vaccine, extending its protective umbrella beyond its primary role of preventing shingles.

The comprehensive investigation involved a review of medical data from over 246,822 adults across the United States, all of whom had a diagnosis of atherosclerotic heart disease. This condition, characterized by the dangerous buildup of plaque in the arteries, is a leading cause of heart attacks, strokes, and other cardiovascular complications globally. The results of this large-scale analysis significantly bolster an accumulating body of evidence suggesting that the shingles vaccine may confer advantages far beyond preventing the painful rash, potentially lowering the risk of severe conditions such as heart disease and even neurodegenerative disorders like dementia.

Unpacking the Cardioprotective Effects of Shingles Vaccination

"This vaccine has been found over and over again to have cardioprotective effects for reducing heart attack, stroke and death," stated Robert Nguyen, MD, a resident physician at the University of California, Riverside, and the lead author of the groundbreaking study. Dr. Nguyen emphasized the consistency of these observations across various populations. He further noted the profound implications for particularly vulnerable groups: "Looking at the highest risk population, those with existing cardiovascular disease, these protective effects might be even greater than among the general public." This highlights a potential amplified benefit for individuals already battling significant health challenges.

The Centers for Disease Control and Prevention (CDC) currently recommends the shingles vaccine for all adults aged 50 years and older, as well as for younger individuals with compromised immune systems, who are at a heightened risk for severe shingles. The vaccine targets herpes zoster, the medical term for shingles, a condition notorious for causing a painful, blistering rash that can lead to debilitating, long-lasting nerve pain known as postherpetic neuralgia (PHN). Shingles develops when the varicella-zoster virus (VZV), the same virus responsible for chickenpox, reactivates in the body, often many years after the initial childhood infection. The VZV lies dormant in nerve cells and can re-emerge, particularly during periods of stress, illness, or age-related weakening of the immune system.

Earlier research has meticulously documented that an active shingles infection can precipitate a systemic inflammatory response, triggering the formation of blood clots near vital organs such as the brain and heart. This inflammatory cascade and subsequent hypercoagulability significantly elevate the risk of acute cardiovascular events, including heart attacks (myocardial infarction), strokes (cerebrovascular accident), and venous thromboembolism. By effectively preventing the onset of shingles, the vaccine plays a critical role in mitigating this dangerous inflammatory response and, consequently, reducing the likelihood of these severe and potentially fatal clotting events.

A Deep Dive into the Study’s Robust Methodology and Striking Findings

To execute this expansive study, researchers leveraged TriNetX, a sophisticated global federated research network that aggregates de-identified electronic medical records from millions of Americans across numerous healthcare organizations. This powerful database allowed for the examination of real-world data from adults aged 50 years or older who had been diagnosed with atherosclerotic disease between the years 2018 and 2025. The analytical cohort was meticulously constructed to ensure comparability, comprising 123,411 individuals who had received at least one dose of either the Shingrix or Zostavax vaccine, meticulously matched with an equal number of individuals who had not been vaccinated. The matching process ensured that both groups were statistically similar across critical demographic variables, including age, gender, race, ethnicity, and socioeconomic factors, as well as pre-existing health conditions such as diabetes, hypertension, and hyperlipidemia, thereby minimizing potential confounding variables.

The researchers precisely focused on heart-related outcomes that occurred within a defined window: between one month and one year following vaccination (or the equivalent timeframe for the unvaccinated control group). Across virtually all measured cardiovascular outcomes, vaccinated individuals consistently demonstrated a significantly lower risk profile. Specifically, they were 46% less likely to experience a major adverse cardiac event (MACE), a composite endpoint often including heart attack, stroke, or cardiovascular death. Furthermore, the vaccinated group exhibited a remarkable 66% lower likelihood of dying from any cause during the observation period. Delving deeper into specific events, the risk of heart attack plummeted by 32%, the risk of stroke decreased by 25%, and the incidence of heart failure was reduced by 25% among those who had received the shingles vaccine.

Dr. Nguyen underscored the profound clinical relevance of these reductions, noting that their magnitude is "substantial and comparable to the benefits seen from quitting smoking," one of the most impactful lifestyle interventions for cardiovascular health. He reiterated that these compelling findings strongly reinforce the existing recommendations from health authorities for all adults over the age of 50 to receive the shingles vaccine.

Public Health Imperative and Countering Misinformation

"Vaccines are one of the most important medicines we have to prevent disease," Dr. Nguyen asserted, highlighting their indispensable role in modern public health. He acknowledged the challenges posed by vaccine hesitancy and misinformation: "Sometimes patients are unsure about whether they should get a vaccine or not, particularly in an age of disinformation. These results provide another reason for them to elect to get the vaccine." This statement resonates with the broader public health objective of promoting evidence-based medical decisions amidst a climate often clouded by unsubstantiated claims.

Contextualizing the Vaccine Landscape: A Brief Timeline

The journey of shingles prevention has seen significant advancements over the past two decades. The first shingles vaccine, Zostavax, a live attenuated vaccine, was approved by the U.S. Food and Drug Administration (FDA) in 2006. While effective, its protection waned over time, and it was contraindicated for immunocompromised individuals. A major leap forward occurred with the approval of Shingrix in 2017. Shingrix is a recombinant subunit vaccine, meaning it contains only a small piece of the virus, making it highly effective (over 90% protection) and suitable for a broader range of patients, including those with weakened immune systems. The CDC subsequently recommended Shingrix as the preferred shingles vaccine.

Prior to the widespread availability of these vaccines, shingles affected approximately one in three people in the United States during their lifetime, leading to millions of cases annually. The economic burden, including healthcare costs for treatment and management of PHN, was substantial. The emerging understanding of its cardiovascular links adds another layer of urgency to widespread vaccination efforts. This current study, presented at ACC.26, builds upon previous observational data and further solidifies the argument for shingles vaccination as a critical tool in cardiovascular disease prevention.

Limitations and Future Directions

While the study’s findings are robust and compelling, the authors acknowledged certain limitations inherent in observational research. The analysis primarily tracked outcomes during the first year after vaccination, meaning the long-term effects beyond this period warrant further investigation. However, this concern is somewhat mitigated by a previous study, published in 2025, which indicated that shingles vaccination was associated with a 23% reduction in cardiovascular events in generally healthy adults, with benefits potentially extending for up to eight years. This suggests that the protective effects may indeed be sustained.

Another crucial consideration is the potential for "healthy user bias." Individuals who choose to get vaccinated may inherently engage in healthier behaviors overall, such as regular exercise, a balanced diet, and adherence to medical advice for other conditions. While the researchers made considerable efforts to adjust for a wide array of health and socioeconomic factors (including issues related to housing and economic circumstances, social environment, employment status, education, and literacy), it remains conceivable that some of the observed benefit could still be influenced by residual confounding from unmeasured variables. Despite this, the study’s exceptionally large sample size and sophisticated statistical approach provide powerful evidence, strongly suggesting that shingles vaccination is independently associated with a clinically meaningful reduction in cardiovascular risk.

Broader Implications for Clinical Practice and Public Health

The implications of this research are far-reaching. For clinicians, particularly cardiologists and primary care physicians, these findings provide an even stronger rationale to actively recommend shingles vaccination to their eligible patients, especially those with existing atherosclerotic heart disease. Integrating vaccination discussions into routine cardiovascular risk assessments could become a new standard of care, offering a dual benefit of preventing shingles and safeguarding cardiovascular health.

From a public health perspective, increasing shingles vaccination rates could lead to a significant reduction in cardiovascular morbidity and mortality at a population level. The economic benefits could also be substantial, with fewer hospitalizations for heart attacks and strokes, and reduced long-term care costs associated with chronic cardiovascular conditions. This study contributes to a growing understanding of how infectious diseases and their prevention can have profound, systemic effects on overall health. It encourages a more holistic approach to patient care, where vaccination is seen not just as protection against a specific pathogen, but as a potential tool for mitigating broader health risks.

Dr. Nguyen is scheduled to formally present the study, titled "Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease," on Monday, March 30, at 12:30 p.m. CT / 17:30 UTC in Posters, Hall E, at the ACC.26 Scientific Session, where it is expected to generate significant discussion among cardiovascular specialists. The findings serve as a powerful reminder of the enduring value of vaccination as a cornerstone of preventive medicine, offering a straightforward yet highly effective intervention with profound potential to improve quality of life and extend healthy lifespans for millions.